Prazitone (; developmental code name AGN-511) is a barbiturate derivative described as an antidepressant which was developed in the 1960s.[1] [2] Unlike most barbiturates, it has little or no sedative effects, instead acting as a non-sedating anxiolytic and antidepressant.[3] The dosage range in humans is around 200–600 mg, although higher doses have been used in trials for the treatment of depression associated with Parkinson's disease.